NV-AMBARELLA
2.1.2020 11:02:12 CET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an artificial intelligence (AI) vision silicon company, today announced that Ambarella and Amazon Web Services, Inc. (AWS) customers can now use Amazon SageMaker Neo to train machine learning (ML) models once and run them on any device equipped with an Ambarella CVflow®-powered AI vision system on chip (SoC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005052/en/
Until now, developers had to manually optimize ML models for devices based on Ambarella AI vision SoCs. This step could add considerable delays and errors to the application development process. Ambarella and AWS collaborated to simplify the process by integrating the Ambarella toolchain with the Amazon SageMaker Neo cloud service. Now, developers can simply bring their trained models to Amazon SageMaker Neo and automatically optimize the model for Ambarella CVflow-powered SoCs.
Customers can build an ML model using MXNet, TensorFlow, PyTorch, or XGBoost and train the model using Amazon SageMaker in the cloud or on their local machine. Then, they can upload the model to their AWS account and use Amazon SageMaker Neo to optimize the model for Ambarella SoCs. They can choose CV25, CV22, or CV2 as the compilation target. Amazon SageMaker Neo compiles the trained model into an executable that is optimized for Ambarella’s CVflow neural network accelerator. The compiler applies a series of optimizations that can make the model run up to 2x faster on the Ambarella SoC. Customers can download the compiled model and deploy it to their fleet of Ambarella-equipped devices. The optimized model runs in the Amazon SageMaker Neo runtime purpose-built for Ambarella SoCs and available for the Ambarella SDK. The Amazon SageMaker Neo runtime occupies less than 10x the disk and memory footprint of TensorFlow, MXNet, or PyTorch, making it much more efficient to deploy ML models on connected cameras.
“Ambarella is in mass production today with CVflow AI vision processors for the home monitoring, enterprise video security, and automotive markets,” said Chris Day, vice president of marketing and business development for Ambarella. “The ability to select an Ambarella SoC and compile a trained ML model with a single click is a powerful tool that makes it possible for our customers to rapidly bring the next generation of AI-enabled products to market.”
Manufactured using an advanced 10-nanometer process, Ambarella’s CVflow SoC family enables the design of compact, high-performance vision systems with ultra-low power operation. For example, the Ambarella CV22 CVflow SoC delivers computer vision processing at full 4K or 8-megapixel resolution at 30 frames per second (fps), while its image signal processor (ISP) provides outstanding imaging in low light conditions and high-contrast scenes, further enhancing the computer vision capabilities of the chip. The CV22 also includes a suite of advanced security features to protect against hacking including secure boot, TrustZone®, I/O virtualization, and support for online upgrades over the air (OTA).
“AWS has the broadest and deepest set of ML and AI services focused on solving some of the toughest challenges facing developers. Amazon SageMaker is a fully managed service that provides every developer and data scientist with the ability to build, train, and deploy machine learning models quickly,” said Bratin Saha, vice president, Machine Learning & Engines, Amazon Web Services, Inc. “We’re excited that VIVOTEK is using SageMaker Neo to simplify the deployment of ML models at the edge on Ambarella CVflow-powered IP cameras.”
VIVOTEK (TWSE:3454), a leading global IP surveillance solution provider and customer of both Ambarella and AWS, will now be able to deploy advanced ML capabilities to a new camera product line—powered by the Ambarella CV series SoCs—more quickly using Amazon SageMaker Neo. Dr. Steve Ma, vice president of engineering, Brand Business Division, VIVOTEK INC. said, “We’re excited that we will be able to explore training and deploying the machine learning models increasingly demanded by our customers to our future Ambarella CV series powered cameras with Amazon SageMaker Neo, potentially saving us months of hand-tuning the individual models for optimal performance on the edge. Using Amazon SageMaker Neo ensures that our IP camera solutions are fully able to leverage the market-leading computer vision capabilities of the Ambarella SoC.”
Ambarella will demonstrate the integration with Amazon SageMaker Neo during CES 2020 to select customers and partners.
The URL for this news release and the related image: https://www.ambarella.com/news-events/
About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. ©2020 Ambarella. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200102005052/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
